Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hermes, B., Schütte, J., . . . Reichardt, P. (2020). Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncol.
Chicago Style CitationJoensuu, Heikki, et al. "Survival Outcomes Associated With 3 Years Vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up." JAMA Oncol 2020.
Cita MLAJoensuu, Heikki, et al. "Survival Outcomes Associated With 3 Years Vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up." JAMA Oncol 2020.